Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells

Zika virus cell tropism in the developing human brain and inhibition by azithromycin

Retallack, H., Di Lullo, E., Arias, C., Knopp, K. A., Laurie, M. T., Sandoval-Espinosa, C., Mancia Leon, W. R., Krencik, R., Ullian, E. M., Spatazza, J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618029113 · Cited by 506

Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye

Jaruratanasirikul, S., Hortiwakul, R., Tantisarasart, T., Phuenpathom, N., & Tussanasunthornwong, S. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.825 · Cited by 108

The Race To Find Antivirals for Zika Virus

Sáiz, J., & Martín-Acebes, M. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00411-17 · Cited by 105

Maternal and transplacental pharmacokinetics of azithromycin

Ramsey, P. S., Vaules, M. B., Vasdev, G., Andrews, W. W., & Ramin, K. D. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.141 · Cited by 100

Safety of macrolides during pregnancy

Lin, K. J., Mitchell, A. A., Yau, W., Louik, C., & Hernández–Dı́az, S. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.12.023 · Cited by 91

Azithromycin in the treatment of COVID-19: a review

Echeverría-Esnal, D., Martín‐Ontiyuelo, C., Navarrete-Rouco, M. E., de Antonio-Cuscó, M., Ferrández, O., Horcajada, J. P., & Grau, S. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1813024 · Cited by 257

Azithromycin Inhibits the Replication of Zika Virus

Bosseboeuf, E., Aubry, M., Nhan, T., Pina, J.-J. D., Rolain, J., Raoult, D., & Musso, D. (2018) · Journal of Antivirals & Antiretrovirals · doi:10.4172/1948-5964.1000173 · Cited by 131

Azithromycin Protects against Zika Virus Infection by Upregulating Virus-Induced Type I and III Interferon Responses

Li, C., Zu, S., Deng, Y., Li, D., Parvatiyar, K., Quanquin, N. M., Shang, J., Sun, N., Su, J., Liu, Z., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00394-19 · Cited by 108

The current understanding and potential therapeutic options to combat COVID-19

Pooladanda, V., Thatikonda, S., & Godugu, C. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117765 · Cited by 90

Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19

Venditto, V. J., Haydar, D., Abdel‐Latif, A., Gensel, J. C., Anstead, M., Pitts, M. G., Creameans, J. W., Kopper, T. J., Peng, C., & Feola, D. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.574425 · Cited by 88

Simultaneous electrochemical detection of azithromycin and hydroxychloroquine based on VS2 QDs embedded N, S @graphene aerogel/cCNTs 3D nanostructure

Mahnashi, H. M., Mahmoud, A. M., Alkahtania, S. A., & El‐Wekil, M. M. (2021) · Microchemical Journal · doi:10.1016/j.microc.2021.105925 · Cited by 74

Repurposing of antibiotics for clinical management of COVID-19: a narrative review

Yacouba, A., Olowo‐okere, A., & Yunusa, I. U. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00444-9 · Cited by 68

The Rationale for Potential Pharmacotherapy of COVID-19

Saber-Ayad, M. M., Saleh, M. A., & Abu‐Gharbieh, E. (2020) · Pharmaceuticals · doi:10.3390/ph13050096 · Cited by 59

Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond

Poddighe, D., & Aljofan, M. (2020) · Antiviral chemistry & chemotherapy · doi:10.1177/2040206620961712 · Cited by 57

Macrolides and COVID-19: An optimum premise

Al-Kuraishy, H. M., Al-Naimi, M. S., Lungnier, C., & Al-Gareeb, A. I. (2020) · Biomedical and Biotechnology Research Journal (BBRJ) · doi:10.4103/bbrj.bbrj_103_20 · Cited by 55

A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19)

Rameshrad, M., Ghafoori, M., Mohammadpour, A. H., Nayeri, M. J. D., & Hosseinzadeh, H. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01901-6 · Cited by 51

Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity

Sturley, S. L., Rajakumar, T., Hammond, N., Higaki, K., Márka, Z., Márka, S., & Munkacsi, A. B. (2020) · Journal of Lipid Research · doi:10.1194/jlr.r120000851 · Cited by 43

Chloroquine as a prophylactic agent against COVID-19?

Gendrot, M., Javelle, É., Clerc, A., Savini, H., & Pradines, B. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105980 · Cited by 44

ICR suckling mouse model of Zika virus infection for disease modeling and drug validation

Wu, Y.-H., Tseng, C.-K., Lin, C.-K., Wei, C.-K., Lee, J.-C., & Young, K.-C. (2018) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006848 · Cited by 35

Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator

Wang, X., Xia, S., Zou, P., & Lu, L. (2019) · Viruses · doi:10.3390/v11111064 · Cited by 27

Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19

Kim, S. B., Ryoo, S., Huh, K., Joo, E., Kim, Y. J., Choi, W. S., Kim, Y., Yoon, Y. K., Heo, J. Y., Seo, Y. B., et al. (2021) · Infection and Chemotherapy · doi:10.3947/ic.2021.0303 · Cited by 26

Can a metabolism-targeted therapeutic intervention successfully subjugate SARS-COV-2? A scientific rational

Mansouri, K., Rastegari‐Pouyani, M., Ghanbari-Movahed, M., Safarzadeh, M., Kiani, S., & Ghanbari‐Movahed, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110694 · Cited by 24

Pandemic COVID-19: Current status and challenges of antiviral therapies

Chan, W., He, B., Wang, X., & He, M. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.07.001 · Cited by 14

Could azithromycin play a role in the treatment of COVID-19? A reviewPreprint

Echeverría-Esnal, D., Martín‐Ontiyuelo, C., Rouco, M. E. N., Antonio, M. D., Ferrández, O., Horcajada, J. P., & Grau, S. (2020) · doi:10.22541/au.159170711.16292378 · Cited by 3

Updated COVID-19 Pharmacotherapy in Different Diseases Such as Cancer

Tolou–Ghamari, Z. (2024) · Coronaviruses · doi:10.2174/0126667975259296240409061101 · Cited by 2

COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection

Gomes, P. S., Machado, P. D. A., Gomes, A. M. O., de Oliveira, A. C., Silva, J. L., & Guedes, H. L. D. M. (2021) · Coronaviruses · doi:10.2174/2666796702999210112202907 · Cited by 2

Reply to Iannetta et al., “Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells”

Sáiz, J., & Martín-Acebes, M. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01192-17 · Cited by 2

Treatment of SARS-CoV-2 (COVID-19): A safety perspective

Davis, J. S., Umeh, U. S., & Saba, R. (2021) · World Journal of Pharmacology · doi:10.5497/wjp.v10.i1.1 · Cited by 1

Reply to Iannetta et al., “Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells”

Sáiz, J., & Martín-Acebes, M. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01192-17 · Cited by 2

Zika Virus Infects Primary Human Glial Cells and Results in Neuroinflammation and Cell Death

Sun, J., Liang, Y., Hu, H., & Zhang, B. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.204.supp.249.13

Azithromycin Inhibits the Replication of Zika Virus

Bosseboeuf, E., Aubry, M., Nhan, T., Pina, J.-J. D., Rolain, J., Raoult, D., & Musso, D. (2018) · Journal of Antivirals & Antiretrovirals · doi:10.4172/1948-5964.1000173 · Cited by 131

The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities

Han, Y.-S., Mésplède, T., Xu, H., Quan, Y., & Wainberg, M. A. (2018) · Journal of Medical Virology · doi:10.1002/jmv.25031 · Cited by 51

Antibiótico impede infecção pelo vírus Zika

Ipê, N. (2016)